Literature DB >> 30796894

Cocaine abuse and midbrain circuits: Functional anatomy of hypocretin/orexin transmission and therapeutic prospect.

Steven J Simmons1, Taylor A Gentile2.   

Abstract

Cocaine abuse remains a pervasive public health problem, and treatments thus far have proven ineffective for long-term abstinence maintenance. Intensive research on the neurobiology underlying drug abuse has led to the consideration of many candidate transmitter systems to target for intervention. Among these, the hypocretin/orexin (hcrt/ox) neuropeptide system holds largely untapped yet clinically viable therapeutic potential. Hcrt/ox originates from the hypothalamus and projects widely across the mammalian central nervous system to produce neuroexcitatory actions via two excitatory G-protein coupled receptor subtypes. Functionally, hcrt/ox promotes arousal/wakefulness and facilitates energy homeostasis. In the early 2000s, hcrt/ox transmission was shown to underlie mating behavior in male rats suggesting a novel role in reward-seeking. Soon thereafter, hcrt/ox neurons were shown to respond to drug-associated stimuli, and hcrt/ox transmission was found to facilitate motivated responding for intravenous cocaine. Notably, blocking hcrt/ox transmission using systemic or site-directed pharmacological antagonists markedly reduced motivated drug-taking as well as drug-seeking in tests of relapse. This review will unfold the current state of knowledge implicating hcrt/ox receptor transmission in the context of cocaine abuse and provide detailed background on animal models and underlying midbrain circuits. Specifically, attention will be paid to the mesoaccumbens, tegmental, habenular, pallidal and preoptic circuits. The review will conclude with discussion of recent preclinical studies assessing utility of suvorexant - the first and only FDA-approved hcrt/ox receptor antagonist - against cocaine-associated behaviors.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Addiction; Cocaine; Dopamine; Hypocretin/orexin; Midbrain; Psychostimulant(s); Reward; Ventral tegmental area

Mesh:

Substances:

Year:  2019        PMID: 30796894      PMCID: PMC6702109          DOI: 10.1016/j.brainres.2019.02.026

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  162 in total

1.  Persistent cue-evoked activity of accumbens neurons after prolonged abstinence from self-administered cocaine.

Authors:  Udi E Ghitza; Anthony T Fabbricatore; Volodymyr Prokopenko; Anthony P Pawlak; Mark O West
Journal:  J Neurosci       Date:  2003-08-13       Impact factor: 6.167

2.  Hypothalamic orexin (hypocretin) neurons express vesicular glutamate transporters VGLUT1 or VGLUT2.

Authors:  Diane L Rosin; Matthew C Weston; Charles P Sevigny; Ruth L Stornetta; Patrice G Guyenet
Journal:  J Comp Neurol       Date:  2003-10-27       Impact factor: 3.215

3.  Optogenetic activation of GABAergic neurons in the nucleus accumbens decreases the activity of the ventral pallidum and the expression of cocaine-context-associated memory.

Authors:  Li Wang; Minjie Shen; Yongchun Yu; Yezheng Tao; Ping Zheng; Feifei Wang; Lan Ma
Journal:  Int J Neuropsychopharmacol       Date:  2014-01-23       Impact factor: 5.176

4.  Dose-dependent differences in short ultrasonic vocalizations emitted by rats during cocaine self-administration.

Authors:  David J Barker; David H Root; Sisi Ma; Shaili Jha; Laura Megehee; Anthony P Pawlak; Mark O West
Journal:  Psychopharmacology (Berl)       Date:  2010-06-23       Impact factor: 4.530

5.  The inhibitory influence of the lateral habenula on midbrain dopamine cells: ultrastructural evidence for indirect mediation via the rostromedial mesopontine tegmental nucleus.

Authors:  Judith Joyce Balcita-Pedicino; Natalia Omelchenko; Roland Bell; Susan R Sesack
Journal:  J Comp Neurol       Date:  2011-04-15       Impact factor: 3.215

6.  Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction.

Authors:  K M Gautvik; L de Lecea; V T Gautvik; P E Danielson; P Tranque; A Dopazo; F E Bloom; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

7.  Projection-Target-Defined Effects of Orexin and Dynorphin on VTA Dopamine Neurons.

Authors:  Corey Baimel; Benjamin K Lau; Min Qiao; Stephanie L Borgland
Journal:  Cell Rep       Date:  2017-02-07       Impact factor: 9.423

8.  A role for lateral hypothalamic orexin neurons in reward seeking.

Authors:  Glenda C Harris; Mathieu Wimmer; Gary Aston-Jones
Journal:  Nature       Date:  2005-08-14       Impact factor: 49.962

9.  Ultrasonic vocalizations: evidence for an affective opponent process during cocaine self-administration.

Authors:  David J Barker; Steven J Simmons; Lisa C Servilio; Danielle Bercovicz; Sisi Ma; David H Root; Anthony P Pawlak; Mark O West
Journal:  Psychopharmacology (Berl)       Date:  2013-11-07       Impact factor: 4.530

10.  GABAergic neurons in the preoptic area send direct inhibitory projections to orexin neurons.

Authors:  Yuki C Saito; Natsuko Tsujino; Emi Hasegawa; Kaori Akashi; Manabu Abe; Michihiro Mieda; Kenji Sakimura; Takeshi Sakurai
Journal:  Front Neural Circuits       Date:  2013-12-02       Impact factor: 3.492

View more
  6 in total

1.  Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?"

Authors:  Morgan H James; Gary Aston-Jones
Journal:  Brain Res       Date:  2020-01-10       Impact factor: 3.252

2.  Identifying roles for peptidergic signaling in mice.

Authors:  Kathryn G Powers; Xin-Ming Ma; Betty A Eipper; Richard E Mains
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-27       Impact factor: 11.205

Review 3.  The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse.

Authors:  Morgan H James; Jennifer E Fragale; Shayna L O'Connor; Benjamin A Zimmer; Gary Aston-Jones
Journal:  Neuropharmacology       Date:  2020-10-19       Impact factor: 5.250

Review 4.  Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.

Authors:  Reda M Chalhoub; Peter W Kalivas
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

5.  Age-specific treatment effects of orexin/hypocretin-receptor antagonism on methamphetamine-seeking behavior.

Authors:  Natalie E Zlebnik; Nathan A Holtz; Victoria C Lepak; Amy T Saykao; Yanan Zhang; Marilyn E Carroll
Journal:  Drug Alcohol Depend       Date:  2021-04-27       Impact factor: 4.852

Review 6.  Targeting the Orexin System for Prescription Opioid Use Disorder.

Authors:  Alessandra Matzeu; Rémi Martin-Fardon
Journal:  Brain Sci       Date:  2020-04-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.